Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Post-Stroke Cognitive Impairment
NCT04854811Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cognitive impairment comparing Placebo with Roflumilast (2 arms). Primary endpoint: Verbal Learning Test (15 words) Delayed Recall at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
roflumilast
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT04854811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854811.